Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1157/13074746 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analysis of early efficacy and immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myeloma.
Sci Rep
January 2025
Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, 29 Xinquan Rd, Fuzhou, 350001, China.
This retrospective study aimed to stress the advantages of autologous hematopoietic stem cell transplantation (auto-HSCT) in treating primary MM. Ninety-four MM patients who underwent initial parallel sequential auto-HSCT were selected. Data on efficacy (efficacy evaluation, renal function and hemoglobin recovery), immune reconstitution (B-cell subsets, immunoglobulin levels, T-cell subsets, NK cells, neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR)) and hematopoietic reconstitution times were collected and analyzed.
View Article and Find Full Text PDFDelayed diagnosis of multiple myeloma in a young patient: a call for vigilance in diagnosis.
BMJ Case Rep
January 2025
Internal Medicine, The George Washington University, Washington, DC, USA.
Multiple myeloma is a rare haematologic malignancy, representing about 1-2% of all cancers and 17% of haematologic malignancies in the US, predominantly affecting older adults and more common in African Americans (AAs) and men. Light-chain multiple myeloma, a subtype accounting for 15% of multiple myeloma cases, often has a more aggressive clinical course. This case report discusses a rare case of an AA female in her early 30s, diagnosed with light-chain multiple myeloma following a pathological rib fracture.
View Article and Find Full Text PDF[Autologous Stem-Cell Transplantation without Transfusion Support in Jehovah's Witness Patients. A case series].
Rev Med Chil
June 2024
Servicio de Medicina física y Rehabilitación, Hospital del Salvador, Santiago, Chile.
Article Synopsis
- Autologous Stem-Cell Transplantation (ASTC) is effective for treating certain blood cancers but can cause severe side effects due to intense chemotherapy.
- The study presents a protocol for performing ASTC without transfusions, catering to patients who decline blood products, such as Jehovah's Witnesses (JW).
- In a small trial with four patients (two with multiple myeloma and two with lymphomas), no serious complications occurred, and all patients remained alive and well at the time of reporting, showcasing the viability of the transfusion-free approach.
Prolonging neutrophil room temperature storage with clinically-approved solutions: Implications for granulocyte transfusion.
J Leukoc Biol
December 2024
Infectious and Immune Diseases Division, CHU de Québec Research Center, Laval University, Québec, QC, Canada.
Introduction: Granulocyte concentrates (GC) are leukocyte preparations enriched in neutrophils that can potentially save neutropenic patients from life-threatening, antimicrobial-resistant infections. The main challenge of GC transfusions is preserving the viability and antimicrobial activity of neutrophils beyond 24 h to reduce the logistical burden on collection centers and increase the availability of this cell therapy. Thus, the aim of this study was to explore extending the ex vivo viability and antimicrobial activity of GC neutrophils up to 72 h with a unique combination of the clinically-approved additives Plasma-Lyte, SAGM, AS-3 and Alburex.
View Article and Find Full Text PDFComparison of Thrombopoietin Receptor Agonists Plus Recombinant Human Thrombopoietin versus Recombinant Human Thrombopoietin Alone for Hematopoietic Reconstruction in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation.
Transplant Cell Ther
December 2024
Xi'an Jiaotong University Second Affiliated Hospital, China; Xi'an Key Laboratory of Diagnosis and Treatment of Hematological Diseases, Xi'an, Shaanxi, China. Electronic address:
Background: Hetrombopag is a novel thrombopoietin receptor agonist that has shown an additive effect in stimulating platelet production when combined with recombinant human thrombopoietin (rhTPO). However, it remains unclear whether this combination can promote hematopoietic reconstruction after autologous stem cell transplant (ASCT).
Purpose: To compare the effect of rhTPO plus thrombopoietin receptor agonists (TPO-RA) versus rhTPO alone on hematopoietic recovery, adverse events, postoperative complications, and cost-effectiveness in patients with newly diagnosed multiple myeloma (NDMM) undergoing ASCT.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!